We are actively seeking partnering opportunities for our lead product candidate and other immunotherapy products.
For DermaVir, we are open to partnering with pharma companies to complete development work including:
- respond to the FDA request for additional information for our Breakthrough Therapy Submission
- joint product development, including a pivotal Phase IIB trial of DermaVir, to be conducted in the US and EU with a patient population of 300. Primary endpoint would be immunogenicity, viral load reduction and further expansion of our safety database
- licensing opportunities of DermaVir on a regional or global basis
Our goal is to file FDA requested documents in 2018 with the stated goal of receiving Breakthrough Therapy Designation and/or fast-track designation.
In addition to DermaVir we are also open to pharma cooperation to develop further products based on our technology platform, including preclinical, and Phase I-I/II trials for:
- Allergy and more.
Please email us to discuss partnership opportunities: